Table 2.

Association of pancreatic cancer susceptibility variants with melanoma risk

Melanoma
ChromosomeSNPGene regionPancreatic cancer OR (95% CI)Minor/ref. allele, MAFaOR (95% CI)P
SNPs observed in GWAS
1rs10919791NR5A2, 1q32.10.77 (0.71–0.84)A/G 0.241.01 (0.85–1.19)0.95
1rs3790843NR5A2, 1q32.10.81 (0.75–0.87)T/C 0.311.05 (0.91–1.22)0.49
1rs3790844NR5A2, 1q32.10.77 (0.71–0.84)G/A 0.261.01 (0.86–1.18)0.94
1rs4465241NR5A2, 1q32.11.25 (1.14–1.37)T/C 0.181.00 (0.83–1.21)0.97
13rs9543325Near FABP5L1, 13q22.11.26 (1.18–1.35)C/T 0.391.05 (0.91–1.21)0.54
13rs9564966Near FABP5L1, 13q22.11.21 (1.13–1.30)A/G 0.341.04 (0.90–1.21)0.60
SNPs in high LD (r2 > 0.5) with SNP of interest
1rs12029406 [rs17665538]bNR5A2, 1q32.10.83 (0.78–0.89)T/C 0.431.40 (1.01–1.93)0.04
5rs401681 [rs402710]bCLPTM1L-TERT, 5p15.331.19 (1.11–1.27)T/C 0.461.15 (1.00–1.33)0.06
9rs505922 [rs630014]bABO1.20 (1.12–1.28)C/T 0.370.96 (0.84–1.10)0.57
  • aMinor and reference alleles and minor allele frequency (MAF) in Europeans.

  • bVariant within brackets is in LD with the targeted SNP and is used to represent the association between the targeted variant and melanoma risk.